Accuray wins FDA nod for iDMS data management system

Accuray (NSDQ:ARAY)  said today it won FDA 510(k) clearance for its iDMS data management system designed for sharing data between the company’s treatment delivery platforms. The Sunnyvale, Calif.-based company said the iDMS system is designed to integrate data from its technology platforms, including the Radixact, TomoTherapy and CyberKnife systems, as well as the company’s Accuray Precision treatment planning and oncology information systems. The iDMS allows users to store and manage all patient and treatment data across multiple devices to allow for more informed, efficient radiation treatments, Accuray said. “This most recent clearance reinforces Accuray’s commitment to providing clinicians with options for seamless, fully integrated treatment planning and data management, enhancing department workflow efficiency. The common database will make it possible for clinicians to use any available Accuray treatment system, expanding patient access to the precision and treatment versatility of our advanced radiation therapy systems,” chief commercial officer Lionel Hadjadjeba said in a press release. Earlier this month, Accuray released data from a prospective study comparing its TomoTherapy intensity-modulated radiation therapy system with Varian Medical‘s (NYSE:VAR), RapidArc radiotherapy system, touting a higher survival rate for patients treated with its TomoTherapy The post Accuray wins FDA nod for iDMS data management system...
Source: Mass Device - Category: Medical Devices Authors: Tags: 510(k) Food & Drug Administration (FDA) Regulatory/Compliance Software / IT Accuray Inc. Source Type: news

Related Links:

OBJECTIVE: To analyze the pattern of local failure in patients with nasopharyngeal carcinoma (NPC) after intensity-modulated radiotherapy (IMRT) and find a more reasonable delineation of the clinical target volume (CTV).METHODS AND MATERIALS: A total of 212 patients with non-metastatic NPC who underwent IMRT were analyzed. Radiation therapy was run at a total dose of 66-74 Gy (2.0-2.2 Gy fractions). The follow-up of local recurrence and the recurrence-related features were analyzed for the original treatment situation. The failures were delimited as “in-field failure” if Vrecur within the 95% isodose curve (V95...
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
Nasopharyngeal carcinoma (NPC) is one of the most common malignant tumors of the head and neck in Southeast Asia and southern China. Although the comprehensive treatment based on intensity-modulated radiation therapy improves outcomes, the five-year survival rate of NPC patients is low, and the recurrence remains high. Radiotherapy resistance is the main cause of poor prognosis in NPC patients. MicroRNAs (miRNAs) are a class of endogenous non-coding RNAs regulating various biological functions in eukaryotes. These miRNAs can regulate the development and progression of nasopharyngeal carcinoma by affecting the proliferation...
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
This study demonstrated that after the completion of 3-4 cycles of chemotherapy with a remission, concurrent chemoradiotherapy with oral etoposide and cisplatin improved survival compared with sequential chemoradiotherapy in LS-SCLC with bulky tumor. Identifier: NCT01745445.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
Radiation therapy remains an essential component of cancer therapy for millions of patients annually in the United States and globally. Radiation therapy involves the focal deposition of ionizing radiation (IR) to the tumor and surrounding at-risk tissue compartments such as regional lymph nodes. The most common treatment approaches include external beam radiation therapy (EBRT) using high-energy photons, electrons, or protons, as well as brachytherapy and radionuclide therapy. Significant technical advances in EBRT and diagnostic imaging over the past several decades have enabled more localized and precise dose deposition...
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Review Article Source Type: research
Target volume delineation has always been but has become increasingly challenging in radiation oncology given the ever more prevalent use of techniques such as 3D conformal radiation therapy and intensity-modulated radiation therapy (IMRT) that enable dose escalation while sparing adjacent normal tissue.
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Short Communication Source Type: research
Conclusion: SRS/FRT remains a useful adjuvant for treatment of residual or recurrent ELSTs, where the risk of revision microsurgical resection is high.
Source: Otology and Neurotology - Category: ENT & OMF Tags: TUMORS OF THE EAR AND CRANIAL BASE Source Type: research
ConclusionsBased on a Markov microsimulation analysis, both AI-alone and APBI-alone are appropriate options for patients 70  years or older with early breast cancer with small cost differences noted. A prospective trial comparing the approaches is warranted.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
ConclusionAdjuvant hypofractionated prone breast IMRT has excellent locoregional control and minimal toxicity.
Source: Journal of Medical Imaging and Radiation Oncology - Category: Radiology Authors: Tags: Radiation Oncology —Original Article Source Type: research
Conclusion: This analysis uses TDABC to estimate the relative internal costs of various RT strategies associated with treating oligometastatic NSCLC. This methodology will become increasingly relevant to each organization in context of the anticipated mandate of alternative/bundled payment models for radiation oncology by the Centers for Medicare and Medicaid Services. PMID: 32529054 [PubMed]
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Tags: Clin Transl Radiat Oncol Source Type: research
Nasopharyngeal carcinoma (NPC), also known as the “Canton tumor”, is one of the most common cancers in southern China. In Hong Kong, the Hong Kong Cancer Registry has noted that NPC was the 6th most common cancer in males with 599 new cases and an incidence rate of 17.7 in 100,000 in 2016. The mortality of NPC ranked 8th in male and 10th in bot h sexes [1]. The first-line treatment for nasopharyngeal cancer is radiation therapy. Xerostomia is a common, debilitating complication of radiation therapy for nasopharyngeal carcinoma [2].
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
More News: Cancer & Oncology | Databases & Libraries | Intensity-Modulated Radiation Therapy | Radiation Therapy | Study